FY2027 EPS Estimates for Amgen Reduced by Erste Group Bank

Amgen Inc. (NASDAQ:AMGN) – Equities research analysts at Erste Group Bank cut their FY2027 earnings estimates for Amgen in a note issued to investors on Wednesday, July 15th. Erste Group Bank analyst H. Engel now anticipates that the medical research company will post earnings per share of $23.58 for the year, down from their previous forecast of $23.62. Erste Group Bank has a “Hold” rating on the stock. The consensus estimate for Amgen’s current full-year earnings is $22.31 per share.

Several other equities research analysts have also recently weighed in on the company. Royal Bank Of Canada reissued a “positive” rating on shares of Amgen in a research note on Thursday, June 18th. Morgan Stanley lowered their price objective on Amgen from $340.00 to $333.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 8th. Piper Sandler reiterated an “overweight” rating on shares of Amgen in a report on Friday, June 12th. Weiss Ratings downgraded Amgen from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday. Finally, Truist Financial boosted their target price on Amgen from $327.00 to $340.00 and gave the company a “hold” rating in a research report on Tuesday, July 7th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $356.62.

Amgen Stock Down 1.4%

Shares of NASDAQ:AMGN opened at $366.29 on Friday. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. Amgen has a 12 month low of $269.77 and a 12 month high of $391.29. The company has a 50-day moving average price of $347.69 and a 200 day moving average price of $350.38. The company has a market cap of $197.69 billion, a price-to-earnings ratio of 25.49, a PEG ratio of 3.76 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. During the same period last year, the company posted $4.90 EPS. The business’s revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS.

Institutional Investors Weigh In On Amgen

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. High Note Wealth LLC raised its position in Amgen by 5.8% during the 4th quarter. High Note Wealth LLC now owns 508 shares of the medical research company’s stock worth $166,000 after buying an additional 28 shares during the last quarter. TAGStone Capital Inc. boosted its holdings in shares of Amgen by 0.7% in the 4th quarter. TAGStone Capital Inc. now owns 4,129 shares of the medical research company’s stock valued at $1,351,000 after acquiring an additional 28 shares during the last quarter. Verus Capital Partners LLC increased its stake in shares of Amgen by 2.3% in the fourth quarter. Verus Capital Partners LLC now owns 1,231 shares of the medical research company’s stock worth $403,000 after acquiring an additional 28 shares during the period. Destination Wealth Management increased its stake in shares of Amgen by 2.1% in the fourth quarter. Destination Wealth Management now owns 1,393 shares of the medical research company’s stock worth $456,000 after acquiring an additional 29 shares during the period. Finally, Breakwater Capital Group raised its holdings in shares of Amgen by 1.4% during the first quarter. Breakwater Capital Group now owns 2,039 shares of the medical research company’s stock worth $717,000 after purchasing an additional 29 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president directly owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.85% of the company’s stock.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen advanced its obesity pipeline with fresh Phase 1 data on AMG 133 injection formats, which could support long-term growth if the program continues to show promise. Amgen Advances Obesity Pipeline With Fresh Data on AMG 133 Injection Formats
• Positive Sentiment: Amgen’s stock was highlighted in market coverage as teasing a buy point, suggesting technical traders may see room for upside if broader market conditions stabilize. Stock Market Today: Dow Sees Red While Amgen Shares Tease A Buy Point (Live Coverage)
• Neutral Sentiment: Amgen remains a candidate for another earnings beat, according to recent coverage pointing to its history of topping estimates and solid fundamentals. Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Erste Group slightly lowered its FY2027 EPS estimate for Amgen to $23.58 from $23.62 and kept a Hold rating, a modest negative for sentiment but not a major change in the outlook. Amgen Inc. (NASDAQ:AMGN) Free Report
• Negative Sentiment: Amgen halted a late-stage bemarituzumab gastric cancer trial, adding uncertainty to part of its oncology pipeline and pressuring investor expectations. Amgen Halts Bemarituzumab Gastric Cancer Trial, Shifting Oncology Expectations
• Negative Sentiment: Amgen also terminated a key Phase 3 rocatinlimab eczema study, another setback that may raise concerns about the durability of its pipeline growth. Amgen’s Rocatinlimab Eczema Trial Termination Jolts Investor Expectations

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.